Trial Profile
A Phase 2, Multicenter, International, Single Arm Study To Assess The Safety And Efficacy Of Single Agent Cc-486 (Oral Azacitidine) In Previously Treated Subjects With Locally Advanced Or Metastatic Nasopharyngeal Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2019
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 04 Nov 2019 Results (n=36) assessing efficacy of oral azacitidine in patients with nasopharyngeal carcinoma published in the European Journal of Cancer
- 29 Nov 2017 Status changed from active, no longer recruiting to completed.
- 03 Jun 2017 This trial has been completed in Spain (end date: 20 Apr 2017).